1stOncology™: Cancer Intelligence Service – Page 14641 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Schrödinger Receives Milestone Payment from Sanofi Collaboration

On July 11, 2019 Schrödinger reported receipt of a preclinical milestone payment from Sanofi in a drug discovery program advancing as part of a multi-year, multi-target collaboration between the two companies (Press release, Schrodinger, JUL 11, 2019, View Source [SID1234537484]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Under the terms of the collaboration, Schrödinger provides advanced molecular simulation and computational design expertise to Sanofi across multiple stages of drug discovery, from target analysis and lead optimization to identification of a development candidate. Earlier this spring, Schrödinger announced the advancement of a separate program in autoimmune disease into clinical trials.

"This is an especially exciting moment in our collaboration with Sanofi as it marks another program advanced," said Karen Akinsanya, Ph.D., Schrödinger’s chief biomedical scientist. "Achieving this milestone is a testament to the value of our ongoing collaboration with partners and our ability to efficiently identify promising therapeutic compounds."

The work with Sanofi is one of several collaborations Schrödinger has established with leading biotech and pharmaceutical companies around the world. These collaborations leverage Schrödinger’s physics-based computational platform to enable rapid iterations of design and analysis of potential therapeutic compounds. Such collaborations have already led to several clinical-stage assets and two FDA-approved oncology drugs. More than two dozen additional programs are moving through discovery and development in indications including oncology, diabetes, metabolic disorders, schizophrenia, and neurodegenerative diseases.

SOTIO initiates first-in-human clinical trial with IL-15 superagonist SO-C101

On July 11, 2019 SOTIO and Cytune Pharma, members of the PPF Group, reported the first dosing of cancer patients with SO-C101, a superagonist fusion protein of interleukin IL-15 (Press release, SOTIO, JUL 11, 2019, View Source [SID1234537483]). The phase I/Ib study (SC103) will evaluate the safety and preliminary efficacy of SO-C101 in patients with selected advanced/metastatic solid tumors.

The first patient was treated with SO-C101 at the Institute Gustave Roussy (France). The SC103 clinical trial will also enrol patients in the Vall d’Hebron cancer center (Spain) and, subject to obtaining all the necessary approvals, at the Yale Cancer Center in New Haven, CT and MD Anderson Cancer Center in Houston, TX. Cytune Pharma is responsible for the clinical development of SO-C101, SOTIO is sponsor of the SC103 clinical trial.

Aurélien Marabelle, M.D., Ph.D., coordinating investigator of the phase I/Ib trial said: "I am very pleased that our medical center has enrolled the first patient in this important clinical trial. We believe that SO-C101 has the potential to make a life-changing difference to many patients with difficult-to-treat forms of cancer. I am looking forward to further advancing this innovative therapy."

"SO-C101 is a very innovative approach which has been validated for its efficacy and safety in preclinical experiments. Since SO-C101 is an ideal combination partner for checkpoint inhibitors, monoclonal antibodies and other well established therapies, the planning for additional combination trials is already ongoing," said Radek Spisek, M.D., Ph.D., CEO of SOTIO.

"I’m excited that after 12 years of research and development at Cytune Pharma, which was based on previous research from INSERM and the University of Nantes and supported by Bpifrance and Atlanpole Biotherapies, our invention has now entered the clinical development phase. I hope that SO-C101 will become a treatment for cancer patients in the future," adds David Bechard, Ph.D., President and COO of Cytune Pharma.

Description of clinical trial
SC103 (Eudra CT: 2012-002814-38): A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in selected patients with advanced/metastatic solid tumors. SOTIO received a positive decision allowing launch of SC103 clinical trial within the EU Voluntary Harmonisation Procedure (VHP) in February 2019.

4SC AG: Positive safety review of Phase Ib/II SENSITIZE study of domatinostat + pembrolizumab in melanoma

On July 11, 2019 4SC AG (4SC, FSE Prime Standard: VSC) reported, that the Safety Review Committee (SRC) consisting of clinical and drug safety experts evaluated the safety data from the third dose cohort in the Phase Ib/II SENSITIZE study (ClinicalTrials.gov identifier: NCT03278665) (Press release, 4SC, JUL 11, 2019, View Source [SID1234537482]).

The SENSITIZE study is a dose escalation study of domatinostat in combination with the checkpoint inhibitor pembrolizumab – an anti-PD-1 antibody approved in the US and the EU as a cancer immunotherapy – to evaluate the safety and tolerability of the combination treatment. The study is being conducted in patients with advanced-stage melanoma who are non-responding or refractory to prior treatment with checkpoint inhibitors.

The combination of domatinostat and pembrolizumab was confirmed as safe and well tolerated by the SRC at this, the third and highest predefined dose cohort.

Frank Hermann, M.D., Chief Development Officer of 4SC, said: "The SENSITIZE study is a key study to evaluate the safety and tolerability of domatinostat in combination with checkpoint inhibitors such as pembrolizumab. We are pleased to see that the highest predefined dose of domatinostat in combination with checkpoint blockade was safe and well tolerated.

In addition, from the sequential biopsies taken in SENSITIZE, we will be able to generate important biological data on the patient’s tumor microenvironment to investigate and support our preclinical data and proposed immuno-modulatory mechanism of action for domatinostat. Data analysis is ongoing, and we intend to publish the clinical and translational data set at an upcoming scientific conference."

Jason Loveridge, Ph.D., CEO of 4SC, added: "Based on the positive safety and tolerability outcome of the first three dose cohorts we will expand the SENSITIZE study and initiate further two cohorts. Taken together, the data from all cohorts will give us important information on how to optimally combine domatinostat with checkpoint blockade and inform our planned clinical studies of domatinostat in other indications.

We plan to initiate several clinical trials of domatinostat in combination with checkpoint inhibitors both in melanoma and Merkel cell carcinoma (MCC) in late 2019 and early 2020 with the intention that one of the MCC studies would be potentially sufficient for registration purposes."

Related articles
8 April 2019, Domatinostat’s mode of action in Merkel cell carcinoma

6 February 2019, First patient enrolled in Phase II study EMERGE of domatinostat (4SC-202) in gastrointestinal cancer

27 December 2018, Positive safety review of 4SC’s Phase Ib/II SENSITIZE study of domatinostat (4SC-202) + pembrolizumab in melanoma

West to Host Second-Quarter 2019 Conference Call

On July 11, 2019 West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, reported that it will release second-quarter 2019 financial results before the market opens on Thursday, July 25, 2019, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time (Press release, West Pharmaceutical Services, JUL 11, 2019, View Source [SID1234537481]). To participate on the call, please dial 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is 6143018.

A live broadcast of the conference call will be available at the Company’s website, www.westpharma.com, in the "Investors" section. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, select "Presentations" in the "Investors" section of the Company’s website.

An online archive of the broadcast will be available at the West website three hours after the live call and will be available through Thursday, August 1, 2019, by dialing 855-859-2056 (U.S.) or 404-537-3406 (International). The conference ID is 6143018.

Leap Therapeutics Announces Common Stock Purchase Agreements For Up to $21 Million with Lincoln Park Capital

On July 11, 2019 Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, reported it has entered into common stock purchase agreements for up to $21 million with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor and current shareholder (Press release, Leap Therapeutics, JUL 11, 2019, View Source [SID1234537480]).

Under a purchase agreement dated July 11, 2019, LPC agreed to purchase $1,000,000 of Leap’s registered common stock at a price of $1.75 per share (the "July 11 Purchase Agreement"). Net proceeds to the Company are approximately $950,000.

Under the terms of a separate common stock purchase agreement (the "Commitment Purchase Agreement"), Leap will have the option, but not the obligation, to sell to LPC up to an additional $20 million in shares of common stock in tranches over a twenty-four month period and once a registration statement relating to the transaction is declared effective. The price of shares sold will be based on the market prices prevailing at the time of each sale to LPC. There is no upper limit as to the price per share that LPC may pay for future stock issuances under the Commitment Purchase Agreement, and Leap will control the timing and amount of any future sales. LPC has no right to require any sales by Leap but is obligated to make purchases according to Leap’s direction. Leap intends to use the net proceeds from the transaction for general corporate purposes, extending its runway to execute its business development and clinical development strategy.

LPC has agreed not to cause or engage in any direct or indirect short selling or hedging of Leap’s common stock. In consideration for entering into the Commitment Purchase Agreement and in lieu of making a cash payment, Leap has issued 330,000 shares of common stock to LPC. Leap maintains the right to terminate the Commitment Purchase Agreement at any time, at its discretion, without any additional cost or penalty.

A description of the July 11 Purchase Agreement, the Commitment Purchase Agreement and the related registration rights agreement is set forth in Leap’s Current Report on Form 8-K filed today with the Securities and Exchange Commission ("SEC").

The shares issued under the July 11 Purchase Agreement are offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-223419) that was previously filed by Leap with the SEC on March 2, 2018 and was declared effective by the SEC on March 16, 2018. A prospectus supplement and the related prospectus will be filed with the SEC today and will be available, for free, on the SEC’s website at View Source

The securities issued as payment for the commitment fee and the securities that may be sold in the future under the Commitment Purchase Agreement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), and have not been registered or qualified under any state securities laws, and therefore may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from such registration requirements, and registration or qualification and under applicable state securities or "Blue Sky" laws or an applicable exemption from such registration or qualification requirements.

offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.